As a Free StocksGuide user, you can view scores for all 7,048 stocks worldwide.
7 Analysts have issued a Sonnet BioTherapeutics Holdings Inc forecast:
7 Analysts have issued a Sonnet BioTherapeutics Holdings Inc forecast:
| Jun '25 |
+/-
%
|
||
| Revenue | 1 1 |
1,567%
1,567%
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -13 -13 |
8%
8%
|
|
| EBIT (Operating Income) EBIT | -13 -13 |
9%
9%
|
|
| Net Profit | -14 -14 |
70%
70%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Sonnet BioTherapeutics Holdings, Inc. engages in the development of biologic drugs with enhanced single or bispecific mechanisms. Its technology utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. The company was founded on April 1, 2020 and is headquartered in Princeton, New Jersey.
| Head office | United States |
| CEO | Raghu Rao |
| Employees | 13 |
| Founded | 2011 |
| Website | www.sonnetbio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


